Maiwald Blog

Maiwald blog articles

European Parliament Supports Use of Some Plants Generated By New Genomic Techniques (NGT) But Opposes Patents for all NGT Plants

In a vote held on 7 February 2024, the European Parliament (EP) approved a proposal to

Continue reading

Determining the value in dispute in patent nullity proceedings if the pharmaceutical product in question does not make use of the teaching of the contested patent – Value in Dispute V

In nullity appeal proceedings, on the application of the appellant the Federal Court of Justice ruled on 23 January 2024 (case no. X ZR 161/23 - not published yet) to signific...

Continue reading

Decision on inventive step casts new light on EBA’s ‘plausibility’ guidance: T 0116/18 and a review after 10 months of G 2/21

In March last year, the much-awaited decision of the Enlarged Board of Appeal (EBA), G 2/21, issued on the topic of “plausibility”, a catchword much appli...

Continue reading

Paris, Munich, Milan – first revision of the UPCA adopted

It has been agreed upon for several weeks and was already confirmed at the meeting of the Administrative Committee of the Unified Patent Court (UPC)

Continue reading

Maiwald is pleased to be a member of the UPCLA network

What is the UPCLA network? The UPCLA network, created in 2014, is a non-exclusive network of European law...

Continue reading

To use or not to use – the nuisance of repeated trademark filings

The so-called grace period for use in the EU Trademark Regulation is intended to give applicants the opportunity to protect their trademark and thus an important marketing too...

Continue reading